clinical trial · NCT06643819
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Essential HypertensionSacubitril∙Valsartan(dose maintenance)Sacubitril∙Valsartan(dose increasing)Valsartan
brief summary
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
started
Oct 14, 2024
primary completion
Mar 31, 2026
completion
Dec 31, 2026
last updated
Dec 11, 2025
official title
A Randomized, Double-blind, Active-controlled, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol